Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 6/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7875234 | 0.93 | DGAT1 (0.42) | HSD17B10KDM4EDGAT1GPR119ALDH1A1 | |
| SCHEMBL2680252 | 0.93 | DGAT1 (0.34) | HSD17B10KDM4EDGAT1ALDH1A1TSHR | |
| SCHEMBL2680249 | 0.93 | DGAT1 (0.34) | HSD17B10KDM4EDGAT1ALDH1A1TSHR | |
| SCHEMBL7874777 | 0.90 | KDM4E (0.38) | HSD17B10KDM4EDGAT1GPR119CHEK1 | |
| SCHEMBL10237375 | 0.86 | DGAT1 (0.35) | HSD17B10KDM4EDGAT1GPR119CHEK1 | |
| SCHEMBL2680067 | 0.86 | DGAT1 (0.41) | HSD17B10KDM4EDGAT1CHEK1ALDH1A1 | |
| SCHEMBL2680071 | 0.86 | DGAT1 (0.41) | HSD17B10KDM4EDGAT1CHEK1ALDH1A1 | |
| SCHEMBL10237460 | 0.85 | KDM4E (0.38) | HSD17B10KDM4EDGAT1GPR119CHEK1 | |
| SCHEMBL10237541 | 0.84 | DGAT1 (0.40) | HSD17B10KDM4EDGAT1GPR119CHEK1 | |
| SCHEMBL7884938 | 0.83 | HSD17B10 (0.43) | HSD17B10KDM4EDGAT1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | HSD17B10 3617/4885KDM4E 1448/4885DGAT1 3031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.